These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 8658174)
41. CTL ontogeny and viral escape: implications for HIV-1 vaccine design. Yang OO Trends Immunol; 2004 Mar; 25(3):138-42. PubMed ID: 15036041 [No Abstract] [Full Text] [Related]
42. Virus load correlates inversely with the expression of cytotoxic T lymphocyte activation markers in HIV-1-infected/AIDS patients showing MHC-unrestricted CTL-mediated lysis. Sindhu ST; Ahmad R; Blagdon M; Ahmad A; Toma E; Morisset R; Menezes J Clin Exp Immunol; 2003 Apr; 132(1):120-7. PubMed ID: 12653846 [TBL] [Abstract][Full Text] [Related]
43. Functional adaptation of Nef to the immune milieu of HIV-1 infection in vivo. Lewis MJ; Balamurugan A; Ohno A; Kilpatrick S; Ng HL; Yang OO J Immunol; 2008 Mar; 180(6):4075-81. PubMed ID: 18322217 [TBL] [Abstract][Full Text] [Related]
44. Stubborn AIDS reservoirs vulnerable to new treatments. Cohen J Science; 1997 May; 276(5314):898-9. PubMed ID: 9163035 [No Abstract] [Full Text] [Related]
45. Genomics and biology come together to fight HIV. Goldstein DB PLoS Biol; 2008 Mar; 6(3):e76. PubMed ID: 18366259 [TBL] [Abstract][Full Text] [Related]
46. Early HIV-specific cytotoxic T lymphocytes and disease progression in children born to HIV-infected mothers. Buseyne F; Burgard M; Teglas JP; Bui E; Rouzioux C; Mayaux MJ; Blanche S; Rivière Y AIDS Res Hum Retroviruses; 1998 Nov; 14(16):1435-44. PubMed ID: 9824321 [TBL] [Abstract][Full Text] [Related]
47. Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors. Betts MR; Krowka JF; Kepler TB; Davidian M; Christopherson C; Kwok S; Louie L; Eron J; Sheppard H; Frelinger JA AIDS Res Hum Retroviruses; 1999 Sep; 15(13):1219-28. PubMed ID: 10480635 [TBL] [Abstract][Full Text] [Related]
48. Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load. Harrer T; Harrer E; Kalams SA; Barbosa P; Trocha A; Johnson RP; Elbeik T; Feinberg MB; Buchbinder SP; Walker BD J Immunol; 1996 Apr; 156(7):2616-23. PubMed ID: 8786327 [TBL] [Abstract][Full Text] [Related]
49. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Rosenberg ES; Billingsley JM; Caliendo AM; Boswell SL; Sax PE; Kalams SA; Walker BD Science; 1997 Nov; 278(5342):1447-50. PubMed ID: 9367954 [TBL] [Abstract][Full Text] [Related]
50. HIV-1 evolution and disease progression. Nowak MA; Anderson RM; Boerlijst MC; Bonhoeffer S; May RM; McMichael AJ Science; 1996 Nov; 274(5289):1008-11. PubMed ID: 8966557 [No Abstract] [Full Text] [Related]
51. HIV-1 mRNA electroporation of PBMC: a simple and efficient method to monitor T-cell responses against autologous HIV-1 in HIV-1-infected patients. Etschel JK; Hückelhoven AG; Hofmann C; Zitzelsberger K; Maurer K; Bergmann S; Mueller-Schmucker SM; Wittmann J; Spriewald BM; Dörrie J; Schaft N; Harrer T J Immunol Methods; 2012 Jun; 380(1-2):40-55. PubMed ID: 22510580 [TBL] [Abstract][Full Text] [Related]
52. CTL responses to HIV and SIV: wrestling with smoke. John M; Mallal S Nat Immunol; 2005 Mar; 6(3):232-4. PubMed ID: 15716970 [No Abstract] [Full Text] [Related]
53. Defying death--HIV mutation to evade cytotoxic T lymphocytes. Lieberman J N Engl J Med; 2002 Oct; 347(15):1203-4. PubMed ID: 12374884 [No Abstract] [Full Text] [Related]
54. Rapid HIV disease progression following superinfection in an HLA-B*27:05/B*57:01-positive transmission recipient. Brener J; Gall A; Hurst J; Batorsky R; Lavandier N; Chen F; Edwards A; Bolton C; Dsouza R; Allen T; Pybus OG; Kellam P; Matthews PC; Goulder PJR Retrovirology; 2018 Jan; 15(1):7. PubMed ID: 29338738 [TBL] [Abstract][Full Text] [Related]
56. HIV-1 dynamics revisited: biphasic decay by cytotoxic T lymphocyte killing? Arnaout RA; Nowak MA; Wodarz D Proc Biol Sci; 2000 Jul; 267(1450):1347-54. PubMed ID: 10972131 [TBL] [Abstract][Full Text] [Related]
57. T lymphocytes of HIV-positive individuals: preloaded guns in spite of highly active antiretroviral therapy? Poli G AIDS; 2004 Jan; 18(2):327-8. PubMed ID: 15075553 [No Abstract] [Full Text] [Related]
58. A lesson from the HIV patient: the immune response is still the bane (or promise) of gene therapy. Koenig S Nat Med; 1996 Feb; 2(2):165-7. PubMed ID: 8574959 [No Abstract] [Full Text] [Related]
59. Potential use of a caspase against HIV. Finkel TH JAMA; 1999 Sep; 282(11):1021-2. PubMed ID: 10493188 [No Abstract] [Full Text] [Related]
60. Virologic and immunologic events in primary HIV infection. Pantaleo G; Graziosi C; Fauci AS Springer Semin Immunopathol; 1997; 18(3):257-66. PubMed ID: 9089948 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]